- Topic
263k Popularity
9k Popularity
9k Popularity
23k Popularity
19k Popularity
- Pin
- Gate July 2025 Transparency Report:
Accelerating Leadership in the Global Crypto Landscape!
#GateTransparencyReport# - 📢 Gate Square Exclusive: #PUBLIC Creative Contest# Is Now Live!
Join Gate Launchpool Round 297 — PublicAI (PUBLIC) and share your post on Gate Square for a chance to win from a 4,000 $PUBLIC prize pool
🎨 Event Period
Aug 18, 2025, 10:00 – Aug 22, 2025, 16:00 (UTC)
📌 How to Participate
Post original content on Gate Square related to PublicAI (PUBLIC) or the ongoing Launchpool event
Content must be at least 100 words (analysis, tutorials, creative graphics, reviews, etc.)
Add hashtag: #PUBLIC Creative Contest#
Include screenshots of your Launchpool participation (e.g., staking record, reward - 🎉 Hey Gate Square friends! Non-stop perks and endless excitement—our hottest posting reward events are ongoing now! The more you post, the more you win. Don’t miss your exclusive goodies! 🚀
🆘 #Gate 2025 Semi-Year Community Gala# | Square Content Creator TOP 10
Only 1 day left! Your favorite creator is one vote away from TOP 10. Interact on Square to earn Votes—boost them and enter the prize draw. Prizes: iPhone 16 Pro Max, Golden Bull sculpture, Futures Vouchers!
Details 👉 https://www.gate.com/activities/community-vote
1️⃣ #Show My Alpha Points# | Share your Alpha points & gains
Post your
Lianhuan Pharmaceutical: The LH-1801 project faces significant uncertainties at multiple critical stages from successful clinical trials to final market launch and profitability.
Jin10 data reported on July 8th that Lianhuan Pharmaceutical issued an announcement regarding abnormal fluctuations in stock trading. The LH-1801 project clinical trial adopts a non-inferiority design, and there is significant uncertainty regarding whether the target can ultimately be achieved. The LH-1801 project faces significant uncertainties in multiple key segments from successful clinical trials to final market launch and profitability. The LH-1801 project is currently still in the R&D stage and is expected to not have a significant impact on the company's operating income and performance for a considerable period of time.